Brief Summary
The study will determine the safety, tolerability, recommended Phase 2 dosethe amount of medication taken (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acutenew, recent, comes with an urgent or significant sense, is sudden, sharp myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN).
Intervention / Treatment
- Drug: BGB-11417
- Drug: Azacitidine
- Drug: Posaconazole
- Drug: BGB-11417
- Drug: BGB-11417
Inclusion Criteria:
- Confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of one of the following by 2016 World Health Organization criteria:
- AML, nonacute promyelocytic leukemia
- MDS
- MDS/MPN
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group performance status of 0 to 2.
- Adequate organ function defined as:
- Creatinine clearance ≥ 50 milliliters/minute (mL/min) (or between 30 and 49 mL/min in unfit AML cohort)
- Adequate liver function
- Life expectancy of > 12 weeks.
- Ability to comply with the requirements of the study.